DAFTAR PUSTAKA

Akbar, M., Misbach, J., Alfa, A.Y., Syamsudin, T., Tjahjadi, Mi., Haddani, M.H., Zakaria, T.S., Birawa, A.B.P., Tugasworo, D., Setyopranoto, I., Purwata, T.E., Made, O.A.I., 2018. Clinical features of transient ischemic attack or ischemic stroke patients at high recurrence risk in Indonesia. Neurol. Asia.

Albert-Weißenberger, C., Sirén, A.-L., Kleinschnitz, C., 2013. Ischemic stroke and traumatic brain injury: The role of the kallikrein–kinin system. Prog. Neurobiol. 101–102, 65–82. https://doi.org/10.1016/j.pneurobio.2012.11.004

Altintas, O., Altintas, M.O., Tasal, A., Kucukdagli, O.T., Asil, T., 2016. The relationship of platelet-to-lymphocyte ratio with clinical outcome and final infarct core in acute ischemic stroke patients who have undergone endovascular therapy. Neurol. Res. 38, 759–765. https://doi.org/10.1080/01616412.2016.1215030

Alzahrani, A., Zhang, X., Albukhari, A., Wardlaw, J.M., Mair, G., 2023. Assessing Brain Tissue Viability on Nonenhanced Computed Tomography After Ischemic Stroke. Stroke 54, 558–566. https://doi.org/10.1161/STROKEAHA.122.041241

Anrather, J., 2017. Pathophysiology of the Peripheral Immune Response in Acute Ischemic Stroke, in: Primer on Cerebrovascular Diseases. Elsevier, pp. 139–145. https://doi.org/10.1016/B978-0-12-803058-5.00028-X

Bai, M., Sun, R., Cao, B., Feng, J., & Wang, J. (n.d.). *Monocyte-Related Cytokines/Chemokines in Cerebral Ischemic Stroke*.

Bibb, R., Eggbeer, D., & Paterson, A. (2015). Medical imaging. In *Medical Modelling* (pp. 7–34). Elsevier. https://doi.org/10.1016/B978-1-78242-300-3.00002-0

Bier, G., Bongers, M.N., Ditt, H., Bender, B., Ernemann, U., Horger, M., 2016. Accuracy of Non-Enhanced CT in Detecting Early Ischemic Edema Using Frequency Selective Non-Linear Blending. PLOS ONE 11, e0147378. https://doi.org/10.1371/journal.pone.0147378

Capirossi, C. (2023). Epidemiology, organization, diagnosis and treatment of acute ke. *European Journal of Radiology Open*.

016. Caplan's Stroke: A Clinical Approach, 5th ed. Cambridge ess. https://doi.org/10.1017/CBO9781316095805

n, L., Hu, W., Feng, X., Qiu, F., Fan, Z., Chen, Q., Qiu, J., Shao, utrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio

as Potential Predictors of Prognosis in Acute Ischemic Stroke. Front. Neurol. 11, 525621. https://doi.org/10.3389/fneur.2020.525621

De Meyer, S. F., Langhauser, F., Haupeltshofer, S., Kleinschnitz, C., & Casas, A. I. (2022). Thromboinflammation in Brain Ischemia: Recent Updates and Future Perspectives. *Stroke*, *53*(5), 1487–1499. https://doi.org/10.1161/STROKEAHA.122.038733

Eren, F., Demir, A., & Eren, G. (2021). The Platelet/Lymphocyte Ratio in Patients with Ischemic Stroke Treated with Intravenous Thrombolysis and Its Relationship with Mortality, Disability, and Prognosis. *Istanbul Medical Journal*, *22*(2), 161–167. https://doi.org/10.4274/imj.galenos.2021.89972

Gore, M., Bansal, K., Khan Suheb, M. Z., Lui, F., & Asuncion, R. M. D. (2024). Lacunar Stroke. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK563216/

Govind, A. S., Sukumar, S., & Dkhar, W. (2015). Grading Of Cerebral Infarction Using Ct-Hounsfield Unit To Report The Hounsfield Unit In Acute, Subacute And Chronic Stroke. *International Journal of Current Research*, *7*.

Greenway K, Knipe H, Gaillard F, et al. Hounsfield unit. Reference article, Radiopaedia.org (Accessed on 21 Sep 2024) https://doi.org/10.53347/rID-38181

Gu, Y., Zhou, C., Piao, Z., Yuan, H., Jiang, H., Wei, H., Zhou, Y., Nan, G., Ji, X., 2022. Cerebral edema after ischemic stroke: Pathophysiology and underlying mechanisms. Front. Neurosci. 16, 988283. https://doi.org/10.3389/fnins.2022.988283

Iadecola, C., Buckwalter, M. S., & Anrather, J. (2020). Immune responses to stroke: Mechanisms, modulation, and therapeutic potential. *Journal of Clinical Investigation*, *130*(6), 2777–2788. https://doi.org/10.1172/JCI135530

Kementrian Kesehatan, Badan Kebijakan Pengembangan Kesehatan. (2023). Laporan Survei Kesehatan Indonesia 2023. Kementrian Kesehatan Republik

hang, J. Y., Kim, S.-H., & Lee, J. E. (2016). Inflammation after oke: The Role of Leukocytes and Glial Cells. *Experimental* , *25*(5), 241–251. https://doi.org/10.5607/en.2016.25.5.241

., Joo, H. J., Shim, G. Y., Chon, J., Chung, S. J., Soh, Y., & Yoo, Neutrophil-to-Lymphocyte Ratio as a Predictor of Short-Term

Functional Outcomes in Acute Ischemic Stroke Patients. *International Journal of Environmental Research and Public Health*, *20*(2), 898. https://doi.org/10.3390/ijerph20020898

Kocaturk, O., Besli, F., Gungoren, F., Kocaturk, M., Tanriverdi, Z., 2019. The relationship among neutrophil to lymphocyte ratio, stroke territory, and 3-month mortality in patients with acute ischemic stroke. Neurol. Sci. 40, 139–146. https://doi.org/10.1007/s10072-018-3604-y

Kömürcü, H.F., Gözke, E., Doğan Ak, P., Kalyoncu Aslan, I., Salt, I., Özgenç Bi¸er, Ç.İ., 2020. Changes in neutrophil, lymphocyte, platelet ratios and their relationship with NIHSS after rtPA and/or thrombectomy in ischemic stroke. J. Stroke Cerebrovasc. Dis. 29, 105004. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105004

Korniluk, A., Koper-Lenkiewicz, O. M., Kamińska, J., Kemona, H., & Dymicka-Piekarska, V. (2019). Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. *Mediators of Inflammation*, *2019*, 1–14. https://doi.org/10.1155/2019/9213074

Lee, J. S., Kim, N. Y., Na, S. H., Youn, Y. H., & Shin, C. S. (2018). Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. *Medicine*, *97*(26), e11138. https://doi.org/10.1097/MD.0000000000011138

Mao, X., Yu, Q., Liao, Y., Huang, Q., Luo, S., Li, S., Qiu, Y., Wu, Y., Zhang, J., Chen, Q., Zhu, M., Li, H., Lin, J., Hong, D., 2022. Lymphocyte-to-Monocyte Ratio Is Independently Associated with Progressive Infarction in Patients with Acute Ischemic Stroke. BioMed Res. Int. 2022, 2290524. https://doi.org/10.1155/2022/2290524

Mohamed, A.-A. B., Elnady, H. M., Alhewaig, H. K., Moslem Hefny, H., & Khodery, A. (2019). The mean platelet volume and plateletcrit as predictors of short-term [illegible] acute ischemic stroke. *The Egyptian Journal of Neurology, [illegible]d Neurosurgery*, *55*(1), 4. https://doi.org/10.1186/s41983-018-

[illegible]ood, A., Liaqat, J., Robert, H.M., Mahmood, R., Khurshid, A., [illegible]ation of Mean Platelet Volume / Platelet Count Ratio with Clinical [illegible] Infarct Volume in Patients with Acute Ischemic Stroke. Pak.

Armed Forces Med. J. 73, 333–36. https://doi.org/10.51253/pafmj.v73i2.7022

Ntaios, G., Gurer, O., Faouzi, M., Aubert, C., Michel, P., 2010. Mean Platelet Volume in the Early Phase of Acute Ischemic Stroke Is Not Associated with Severity or Functional Outcome. Cerebrovasc. Dis. 29, 484–489. https://doi.org/10.1159/000297964

Park, M.-G., Kim, M.-K., Chae, S.-H., Kim, H.-K., Han, J., Park, K.-P., 2018. Lymphocyte-to-monocyte ratio on day 7 is associated with outcomes in acute ischemic stroke. Neurol. Sci. 39, 243–249. https://doi.org/10.1007/s10072-017-3163-7

Payabvash, S., Taleb, S., Benson, J. C., & McKinney, A. M. (2017). Acute Ischemic Stroke Infarct Topology: Association with Lesion Volume and Severity of Symptoms at Admission and Discharge. *American Journal of Neuroradiology*, *38*(1), 58–63. https://doi.org/10.3174/ajnr.A4970

Pensato, U., Demchuk, A.M., Menon, B.K., Nguyen, T.N., Broocks, G., Campbell, B.C.V., Gutierrez Vasquez, D.A., Mitchell, P.J., Hill, M.D., Goyal, M., Ospel, J.M., 2025. Cerebral Infarct Growth: Pathophysiology, Pragmatic Assessment, and Clinical Implications. Stroke 56, 219–229. https://doi.org/10.1161/STROKEAHA.124.049013

Rawish, E., Nording, H., Münte, T., Langer, H.F., 2020. Platelets as Mediators of Neuroinflammation and Thrombosis. Front. Immunol. 11, 548631. https://doi.org/10.3389/fimmu.2020.548631

Rehman, S., Nadeem, A., Akram, U., Sarwar, A., Quraishi, A., Siddiqui, H., Malik, M. A. J., Nabi, M., Ul Haq, I., Cho, A., Mazumdar, I., Kim, M., Chen, K., Sepehri, S., Wang, R., Balar, A. B., Lakhani, D. A., & Yedavalli, V. S. (2024). Molecular Mechanisms of Ischemic Stroke: A Review Integrating Clinical Imaging and Therapeutic Perspectives. *Biomedicines*, *12*(4), 812. https://doi.org/10.3390/biomedicines12040812

[illegible], L., & Gao, Y. (2017). Lymphocyte-to-Monocyte Ratio: A Novel [illegible]he Prognosis of Acute Ischemic Stroke. *Journal of Stroke and [illegible]ular Diseases*, *26*(11), 2595–2602. [illegible]/10.1016/j.jstrokecerebrovasdis.2017.06.019

[illegible] S., Zsóri, K. S., Csiki, Z., Bereczky, Z., & Shemirani, A. H. [illegible]et count and mean volume in acute stroke: A systematic review

and meta-analysis. *Platelets*, *31*(6), 731–739. https://doi.org/10.1080/09537104.2019.1680826

Schneider, A. M., Neuhaus, A. A., Hadley, G., Balami, J. S., Harston, G. W., DeLuca, G. C., & Buchan, A. M. (2023). Posterior circulation ischaemic stroke diagnosis and management. *Clinical Medicine*, *23*(3), 219–227. https://doi.org/10.7861/clinmed.2022-0499

Sharma, D., Gandhi, N., 2021. Role of Platelet to Lymphocyte Ratio (PLR) and its Correlation with NIHSS (National Institute of Health Stroke Scale) for Prediction of Severity in Patients of Acute Ischemic Stroke. J. Assoc. Physicians India 69, 56–60.

Shen, W.-C. (2021). *Diagnostic Neuroradiology: A Practical Guide and Cases*. Springer Singapore. https://doi.org/10.1007/978-981-15-4051-6

Sims, J. R., Gharai, L. R., Schaefer, P. W., Vangel, M., Rosenthal, E. S., Lev, M. H., & Schwamm, L. H. (2009). ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. *Neurology*, *72*(24), 2104–2110. https://doi.org/10.1212/WNL.0b013e3181aa5329

Soliman, R. H., Oraby, M. I., Fathy, M., & Essam, A. M. (2018). Risk factors of acute ischemic stroke in patients presented to Beni-Suef University Hospital: Prevalence and relation to stroke severity at presentation. *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, *54*(1), 8. https://doi.org/10.1186/s41983-018-0012-4

Song, Q., Pan, R., Jin, Y., Wang, Y., Cheng, Y., Liu, J., Wu, B., & Liu, M. (2020). Lymphocyte-to-monocyte ratio and risk of hemorrhagic transformation in patients with acute ischemic stroke. *Neurological Sciences*, *41*(9), 2511–2520. https://doi.org/10.1007/s10072-020-04355-z

Song, S.-Y., Zhao, X.-X., Rajah, G., Hua, C., Kang, R., Han, Y., Ding, Y., & Meng, R. (2019). Clinical Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Patients With Ischemic Stroke or Hemorrhagic Stroke: An Updated Meta-[illegible] *Frontiers in Neurology*, *10*, 1032. [illegible]/10.3389/fneur.2019.01032

[illegible]da, A., Data, K., Walczak, K., Nowocień, M., Frankowska, E., & (2019a). The mean platelet volume on admission predicts [illegible]troke outcomes in patients treated with IV thrombolysis. *Clinical*

Interventions in Aging, *Volume 14*, 493–503. https://doi.org/10.2147/CIA.S195451

Tokgoz, S., Keskin, S., Kayrak, M., Seyithanoglu, A., & Ogmegul, A. (2014). Is Neutrophil/Lymphocyte Ratio Predict to Short-term Mortality in Acute Cerebral Infarct Independently from Infarct Volume? *Journal of Stroke and Cerebrovascular Diseases*, *23*(8), 2163–2168. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.04.007

Wu, L., Zou, S., Wang, C., Tan, X., & Yu, M. (2019). Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in Chinese Han population from Chaoshan region in South China. *BMC Cardiovascular Disorders*, *19*(1), 125. https://doi.org/10.1186/s12872-019-1110-7

Xu, J.-H., He, X.-W., Li, Q., Liu, J.-R., Zhuang, M.-T., Huang, F.-F., & Bao, G.-S. (2019). Higher Platelet-to-Lymphocyte Ratio Is Associated With Worse Outcomes After Intravenous Thrombolysis in Acute Ischaemic Stroke. *Frontiers in Neurology*, *10*, 1192. https://doi.org/10.3389/fneur.2019.01192

Yao, Y., Cao, X., Zou, R., Wen, H., Zhang, S., Xu, H., Guo, X., & Guo, Y. (2022). Study on the Baseline Factors and Platelet Indices That Predict Outcome of Acute Ischemic Stroke Patients after Thrombolytic Therapy. *Cerebrovascular Diseases*, *51*(3), 357–364. https://doi.org/10.1159/000519705

Zhang, D., Ren, J., Luo, Y., He, Q., Zhao, R., Chang, J., Yang, Y., & Guo, Z.-N. (2021). T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights. *Frontiers in Immunology*, *12*, 707972. https://doi.org/10.3389/fimmu.2021.707972

Zhang, Y.X., Shen, Z.Y., Jia, Y.C., Guo, X., Guo, X.S., Xing, Y., Tian, S.J., 2023. The Association of the Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio and Systemic Inflammation Response Index with Short-Term Functional Outcome in Patients with Acute Ischemic Stroke. J. Inflamm. Res. Volume 16, 3619–3630. https://doi.org/10.2147/JIR.S418106

Ren, K., Cong, R., Zhu, X., Zhu, L., & Wang, T. (2021a). The prediction significance of Hounsfield unit value for stroke patients intravenous thrombolysis. *BMC Medical Imaging*, *21*(1), 62. https://doi.org/10.1186/s12880-021-00592-6

Lampiran 1
Rekomendasi Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari ,MMed,PhD, SpGK. TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 1019/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 20 Nopember 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24100861	No Sponsor	
Peneliti Utama	**dr. Zulia Indriani Masnady**	Sponsor	
Judul Peneliti	HUBUNGAN PARAMETER INFLAMASI TERHADAP NILAI HOUNSFIELD UNIT DAN VOLUME INFARK PADA PASIEN STROKE ISKEMIK AKUT		
No Versi Protokol	1	Tanggal Versi	25 Oktober 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohursodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **20 Nopember 2024** sampai **20 Nopember 2025**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	**Prof. dr. Muh Nasrum Massi,PhD,SpMK, Subsp. Bakt(K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2
Data Penelitian

No	Nama	P/L	Usia	Onset (jam-hari)	Leukosit	Platelet	MPV	Neutrofil	Monosit	Limfosit	Neutrofil Absolute	Monosit Absolute	Limfosit Absolute	RNL	RPL	RLM	HU	Volume Infark (cm3)	HT	HF	Merokok	Dislipidemia
1	M	P	57	3	8.55	283	9	70.3	9	18.7	6.01065	0.7695	1.59885	3.759358289	177.0022203	2.077777778	16	3.25	ada			ada
2	RD	P	54	1	7.4	253	9	81.8	3.7	12.1	6.0532	0.2738	0.8954	6.760330579	282.5552826	3.27027027	19	186.67	ada			ada
3	AA	L	59	1	10.4	288	8	72.6	4.8	19.4	7.5504	0.4992	2.0176	3.742268041	142.7438541	4.041666667	25	1.01				
4	MJ	L	68	8jam	8.1	194	10.9	88.3	2.2	9.4	7.1523	0.1782	0.7614	9.393617021	254.7938009	4.272727273	20	62.22	ada			
5	HMM	L	70	9jam	13.6	402	9.9	77.3	10.6	11.6	10.5128	1.4416	1.5776	6.663793103	254.8174442	1.094339623	18	74.33	ada	ada		
6	LM	P	50	7	9.7	247	9.7	77.3	6.2	15.1	7.4981	0.6014	1.4647	5.119205298	168.6352154	2.435483871	22	3.99	ada			ada
7	SR	P	58	14 jam	12.49	456	9.1	77.6	3.4	18.2	9.69224	0.42466	2.27318	4.263736264	200.6000405	5.352941176	19	3.03	ada			
8	F	P	59	3	11.2	259	10.6	71.9	6.3	17	8.0528	0.7056	1.904	4.229411765	136.0294118	2.698412698	17	5.6				ada
9	MYP	P	61	6	21.5	219	11	69.6	5.6	24.6	14.964	1.204	5.289	2.829268293	41.40669314	4.392857143	16	12.32	ada			ada
10	MKP	L	66	7	10.6	280	10.5	63.4	11.4	18	6.7204	1.2084	1.908	3.522222222	146.7505241	1.578947368	24	281.62	ada	ada		
11	JUFRI	P	62	3	8.9	347	8.5	42.8	10.3	38.5	3.8092	0.9167	3.4265	1.111688312	101.269517	3.737864078	18	1.27	ada			ada
12	PN	L	70	1	13.5	256	8.9	82.9	7.2	8.2	11.1915	0.972	1.107	10.1097561	231.2556459	1.138888889	24	12.24	ada			
13	PM	L	44	3	9.7	204	10	48.3	6.8	38	4.6851	0.6596	3.686	1.271052632	55.34454693	5.588235294	22	1.51				ada
14	M	L	55	1	6.8	190	9.6	56.2	6.9	32.5	3.8216	0.4692	2.21	1.729230769	85.97285068	4.710144928	23	1.22	ada	ada		
15	MTM	L	69	6	12.8	309	8.8	74.9	8.6	14.3	9.5872	1.1008	1.8304	5.237762238	168.8155594	1.662790698	20	240.41	ada	ada		
16	L	L	65	5	11.6	214	9	76.7	4.6	6	8.8972	0.5336	0.696	12.78333333	307.4712644	1.304347826	19	4.01	ada			
17	HT	P	70	2	12.2	722	9.4	73.1	6.2	9.9	8.9182	0.7564	1.2078	7.383838384	597.7810896	1.596774194	23	97.8	ada			
18	SST	P	70	7	6.5	436	9.3	53.2	12.7	33.8	3.458	0.8255	2.197	1.573964497	198.4524351	2.661417323	19	0.85		ada		
19	SDA	L	61	1	17.8	237	9.9	87.9	5.8	6.1	15.6462	1.0324	1.0858	14.40983607	218.2722417	1.051724138	25	403.09	ada		ada	
20	IT	P	70	2	11	287	10.6	76.6	10.8	12.5	8.426	1.188	1.375	6.128	208.7272727	1.157407407	24	229.15	ada	ada		
21	AS	P	53	3	10.2	287	8.4	79.6	7	12.1	8.1192	0.714	1.2342	6.578512397	232.5392967	1.728571429	23	271.57	ada			
22	RWP	P	50	1	7.7	339	9.6	54.6	8.3	32.6	4.2042	0.6391	2.5102	1.674846626	135.0490001	3.927710843	19	0.77	ada			
23	R	P	56	2	8.9	368	9.5	60.6	8.9	26.3	5.3934	0.7921	2.3407	2.30418251	157.2179263	2.95505618	16	1.57				
24	S	P	70	2	12.7	252	9	83.4	4.5	11.6	10.5918	0.5715	1.4732	7.189655172	171.0562042	2.577777778	17	1.55				
25	S	P	42	1	5.4	219	8.7	48.2	8.6	39.2	2.6028	0.4644	2.1168	1.229591837	103.4580499	4.558139535	20	1.26				ada
26	H	P	46	1	8.8	303	9.2	72.6	4.8	20.9	6.3888	0.4224	1.8392	3.473684211	164.7455415	4.354166667	21	1.37	ada			ada
27	PK	L	63	3	18.1	192	9.6	92	4.1	3.5	16.652	0.7421	0.6335	26.28571429	303.0781373	0.853658537	20	534.92	ada			
28	SN	P	70	3	5	279	8.6	57.8	13.1	26.5	2.89	0.655	1.325	2.181132075	210.5660377	2.022900763	22	92.9				
29	TA	P	70	1	10	84	11.2	75.1	8.8	14.7	7.51	0.88	1.47	5.108843537	57.14285714	1.670454545	21	240.74	ada			
30	RSP	L	41	7	24.8	354	10.1	85.7	8.3	5.8	21.2536	2.0584	1.4384	14.77586207	246.1067853	0.698795181	23	8.29	ada			
31	HH	L	61	1	9.3	231	9.2	73.6	10	13.1	6.8448	0.93	1.2183	5.618320611	189.6084708	1.31	18	2.43	ada			
32	DK	L	56	1	18.1	247	9.9	86.9	7	5.9	15.7289	1.267	1.0679	14.72881356	231.2950651	0.842857143	14	126.12	ada			
33	J	L	42	4	17.3	143	11	91.4	6.4	1.7	15.8122	1.1072	0.2941	53.76470588	486.2291738	0.265625	23	369.28	ada		ada	
34	S	L	56	4	7.6	165	10.6	69.3	12.2	16.1	5.2668	0.9272	1.2236	4.304347826	134.8479895	1.319672131	18	33.33	ada			ada
35	YRM	P	56	2	13.5	271	10.1	69.9	3.5	24.6	9.4365	0.4725	3.321	2.841463415	81.60192713	7.028571429	20	1.22	ada			
36	MA	P	70	3	4.4	111	11.1	74.3	12.2	13.5	3.2692	0.5368	0.594	5.503703704	186.8686869	1.106557377	18	2.16	ada			
37	A	L	54	7 jam	10.1	260	9.7	75.8	6.8	16	7.6558	0.6868	1.616	4.7375	160.8910891	2.352941176	26	2	ada			
38	S	L	56	4	14.8	228	9.8	85.7	5.5	8.4	12.6836	0.814	1.2432	10.20238095	183.3976834	1.527272727	24	285.57	ada	ada		
39	MTB	L	40	2	15.5	371	8.9	76.3	4.3	18.6	11.8265	0.6665	2.883	4.102150538	128.6853972	4.325581395	28	1.38	ada			ada
40	HJ.H	P	70	1	6.3	197	12.1	59.4	7.1	29.6	3.7422	0.4473	1.8648	2.006756757	105.6413556	4.169014085	20	1.09	ada			ada
41	HJ.PM	P	53	2	20.2	152	11.9	86.9	6.7	6.2	17.5538	1.3534	1.2524	14.01612903	121.3669754	0.925373134	21	368.13	ada			
42	G	L	56	1	6.2	198	9.2	58.2	6.4	31.2	3.6084	0.3968	1.9344	1.865384615	102.3573201	4.875	17	1.5	ada			
				4	9.3	222	9.3	75.6	5.4	16.3	7.0308	0.5022	1.5159	4.63803681	146.4476549	3.018518519	19	155.84	ada			
				1	11	229	9.3	64.2	7.2	26.3	7.062	0.792	2.893	2.441064639	79.15658486	3.652777778	20	161.34	ada			ada
				1	7.7	258	8.7	66	9.1	20.2	5.082	0.7007	1.5554	3.267326733	165.8737302	2.21978022	20	2.4	ada			ada
				1	14.2	120	9.9	85.5	4.5	9.6	12.141	0.639	1.3632	8.90625	88.02816901	2.133333333	25	127.09			ada	
				1	4.3	203	9.2	53.8	8.2	32.2	2.3134	0.3526	1.3846	1.670807453	146.6127401	3.926829268	20	1.01				
				1	7.3	274	10.3	41.2	7	48	3.0076	0.511	3.504	0.858333333	78.19634703	6.857142857	15	1.16	ada			
				3	11.7	361	10	55.6	7	23.6	6.5052	0.819	2.7612	2.355932203	130.7402579	3.371428571	24	1.08	ada			
				2	9	190	10	70.3	5.7	22.4	6.327	0.513	2.016	3.138392857	94.24603175	3.929824561	15	2.67				ada
				1	12.6	199	9.7	77.9	8	13.8	9.8154	1.008	1.7388	5.644927536	114.4467449	1.725	22	230.2		ada	ada	
				7	7.5	176	10.4	53.9	10.9	31.7	4.0425	0.8175	2.3775	1.700315457	74.02733964	2.908256881	21	1.79	ada			
				7	4.9	163	12.4	62.4	7.8	21.4	3.0576	0.3822	1.0486	2.91588785	155.4453557	2.743589744	17	1.27	ada			
				1	9.4	315	9.6	66.9	7.5	23.7	6.2886	0.705	2.2278	2.82278481	141.3950983	3.16	23	1.68	ada			ada
				5	20.7	252	11	78.4	6.6	14.5	16.2288	1.3662	3.0015	5.406896552	83.95802099	2.196969697	19	10.93	ada			
				1	14.5	301	9.3	85	4.6	10.3	12.325	0.667	1.4935	8.252427184	201.5400067	2.239130435	22	8.74	ada			

No	Nama	P/L	Usia	Onset (hari)	Leukosit	Platelet	MPV	Neutrofil	Monosit	Limfosit	Neutrofil Absolute	Monosit Absolute	Limfosit Absolute	RNL	RPL	RLM	HU	Volume Infark (cm3)	HT	HF	Merokok	Dislipidemia
57	SBK	P	64	14 jam	6.7	237	8.8	63.8	6.1	28.1	4.2746	0.4087	1.8827	2.270463	125.883	4.606557	17	0.28	ada			
58	AT	L	54	5	10.8	250	11.3	68	9.1	17.2	7.344	0.9828	1.8576	3.953488	134.5823	1.89011	21	153.67	ada			
59	AK	L	53	1	10.7	229	9.2	70.6	4.2	22.4	7.5542	0.4494	2.3968	3.151786	95.54406	5.333333	22	1.87	ada			ada
60	D	P	57	1	11.2	322	8.9	78.5	6.5	13.9	8.792	0.728	1.5568	5.647482	206.8345	2.138462	22	169.12		ada		
61	SDM	L	65	7	10.1	262	11	64.3	7.5	25	6.4943	0.7575	2.525	2.572	103.7624	3.333333	17	1.7	ada	ad	ada	
62	S	L	40	1	6.4	335	8.6	60.8	9.2	28	3.8912	0.5888	1.792	2.171429	186.942	3.043478	22	2.49	ada			
63	H.MA	L	64	1	10	257	8.8	65.1	10.8	20.9	6.51	1.08	2.09	3.114833	122.9665	1.935185	15	1.63	ada			
64	S	L	59	4	10	176	8.9	64.5	4.3	19.5	6.45	0.43	1.95	3.307692	90.25641	4.534884	16	2.19	ada			
65	M	P	68	2	9.8	151	9.5	90.5	3.1	5.7	8.869	0.3038	0.5586	15.87719	270.3187	1.83871	26	40.18				
66	M	L	69	16 jam	9.2	236	11.1	70.3	8.1	19.5	6.4676	0.7452	1.794	3.605128	131.5496	2.407407	21	1.33	ada			
67	AR	L	51	7	8.1	221	10	47	10	28.7	3.807	0.81	2.3247	1.637631	95.06603	2.87	23	1.29	ada			
68	HJ.S	P	40	1	9.5	299	9.5	69.5	7.8	15.4	6.6025	0.741	1.463	4.512987	204.3746	1.974359	20	5.46				ada
69	A	L	34	5	7.7	233	9.8	54.7	8.5	32.8	4.2119	0.6545	2.5256	1.667683	92.25531	3.858824	26	11.67				ada
70	SS	L	52	7	7.1	210	9.6	53	10	33.7	3.763	0.71	2.3927	1.5727	87.76696	3.37	18	4.87	ada			
71	SDT	L	47	7	7.1	187	10.6	57.4	9.5	27.7	4.0754	0.6745	1.9667	2.072202	95.08313	2.915789	20	1.71	ada	ada		
72	AK	L	57	1	14.8	297	9.4	85.8	8.6	5.5	12.6984	1.2728	0.814	15.6	364.8649	0.639535	24	17.69	ada	ada		ada
73	LS	L	52	19 jam	8.3	356	9.7	63.8	4.4	28.7	5.2954	0.3652	2.3821	2.222997	149.448	6.522727	19	19.06	ada		ada	
74	ADH	L	52	2	8.7	304	8.4	44.3	11.6	39.6	3.8541	1.0092	3.4452	1.118687	88.23871	3.413793	16	1.61			ada	
75	S	L	57	1	12.1	202	9.2	90.7	3.5	5.6	10.9747	0.4235	0.6776	16.19643	298.111	1.6	20	10.36	ada			
76	MA	P	45	1	22	235	9.7	93.7	2.5	3.2	20.614	0.55	0.704	29.28125	333.8068	1.28	20	4.38	ada			
77	R	L	51	2	5.9	237	9.2	43.7	5.6	50	2.5783	0.3304	2.95	0.874	80.33898	8.928571	18	1.26			ada	
78	AF	L	36	1	8.2	202	8.2	77.9	3.5	15.3	6.3878	0.287	1.2546	5.091503	161.0075	4.371429	19	2.92	ada		ada	
79	NT	P	64	2	12.8	271	9.9	68.5	6.3	23.9	8.768	0.8064	3.0592	2.866109	88.58525	3.793651	17	1.04	ada			ada
80	AR	L	64	4	11.5	250	9	60.8	6.6	20.9	6.992	0.759	2.4035	2.909091	104.015	3.166667	22	130.25	ada			ada
81	MA	L	59	4	12.7	260	8.8	82.9	5.8	9.9	10.5283	0.7366	1.2573	8.373737	206.7923	1.706897	21	3.67				
82	MJS	L	70	1	13.9	178	10.6	76.2	10.5	12.8	10.5918	1.4595	1.7792	5.953125	100.045	1.219048	20	102.38	ada	ada		
83	R	P	69	7	8.3	489	9	56.8	13.5	24.8	4.7144	1.1205	2.0584	2.290323	237.5632	1.837037	22	44.97	ada	ada		
84	ARK	L	58	2	9.6	242	10.4	68.7	8	22.3	6.5952	0.768	2.1408	3.080717	113.0419	2.7875	20	50.28	ada			
85	EJ	L	57	1	8.1	278	9.4	63	12.3	22.5	5.103	0.9963	1.8225	2.8	152.5377	1.829268	20	1.42	ada	ada		
86	HST	P	57	2	7.5	232	8.5	65.6	5.7	25.3	4.92	0.4275	1.8975	2.592885	122.2661	4.438596	20	4.22	ada			
87	IA	L	60	1	10.2	248	9.3	58.7	9.8	28.3	5.9874	0.9996	2.8866	2.074205	85.91422	2.887755	18	1.2				
88	RJ	L	34	7	12.6	399	8.5	50.4	7.2	37.5	6.3504	0.9072	4.725	1.344	84.44444	5.208333	22	149.97				ada
89	K	P	70	7 jam	10.5	334	8.4	62.1	9.6	24.9	6.5205	1.008	2.6145	2.493976	127.7491	2.59375	19	8.38	ada			
90	T	L	64	1	9.3	367	9.9	92.3	1.3	6.4	8.5839	0.1209	0.5952	14.42188	616.5995	4.923077	16	12.89	ada		ada	
91	K	P	42	2	17.5	339	9.4	74.6	4	18.7	13.055	0.7	3.2725	3.989305	103.5905	4.675	19	0.71	ada			
92	NB	P	64	1	10.4	317	8.6	60.5	7.1	30.6	6.292	0.7384	3.1824	1.977124	99.61036	4.309859	32	0.53	ada			
93	HJ.H	P	55	6	8.5	229	9.3	71.1	6.8	17.5	6.0435	0.578	1.4875	4.062857	153.9496	2.573529	20	3.09				
94	KA	L	49	1	8.6	266	9.3	61.7	6.3	29.5	5.3062	0.5418	2.537	2.091525	104.8482	4.68254	21	1.64	ada			
95	MS	L	63	3	9.8	210	11.6	76.5	10.5	11.6	7.497	1.029	1.1368	6.594828	184.7291	1.104762	24	99.45	ada			
96	R	P	53	7	8.9	406	8.7	76.4	4.4	18.8	6.7996	0.3916	1.6732	4.06383	242.6488	4.272727	16	2.05	ada			
97	N	L	60	1	16.8	251	8.4	74.2	5.2	18.4	12.4656	0.8736	3.0912	4.032609	81.19824	3.538462	20	1.34	ada			
				1	11	228	10	81.2	7.8	9.6	8.932	0.858	1.056	8.458333	215.9091	1.230769	20	234.57	ada			
				2	8.3	267	9.2	60.5	8.6	24.8	5.0215	0.7138	2.0584	2.439516	129.7124	2.883721	16	1.53				
				1	6.8	394	8.8	62	6.6	28.3	4.216	0.4488	1.9244	2.190813	204.7391	4.287879	15	1.39	ada			
				2	17.6	251	11.1	78.1	8.8	12.9	13.7456	1.5488	2.2704	6.054264	110.5532	1.465909	16	25.1				ada
				1	11.5	205	9.1	86.5	9	4.4	9.9475	1.035	0.506	19.65909	405.1383	0.488889	22	42.83				
				1	9.4	164	9.9	78.6	4.9	15.9	7.3884	0.4606	1.4946	4.943396	109.7284	3.244898	20	2.33	ada			
				1	9.2	407	8.9	58.8	8.7	30.3	5.4096	0.8004	2.7876	1.940594	146.0037	3.482759	15	1.23	ada			
				1	7.4	198	9	42.6	8.9	12.8	3.1524	0.6586	0.9472	3.328125	209.0372	1.438202	19	2.75	ada			
				4	18.1	209	10.2	84.8	6.2	8.9	15.3488	1.1222	1.6109	9.52809	129.7411	1.435484	19	64.13			ada	
				2	11.2	227	9.7	73.4	5.2	20.1	8.2208	0.5824	2.2512	3.651741	100.8351	3.865385	21	2.8	ada			
				1	6.7	218	9.9	76.1	4.3	18	5.0987	0.2881	1.206	4.227778	180.7629	4.186047	16	1.13	ada			ada
				2	8.3	311	9.1	61.4	6.3	26.4	5.0962	0.5229	2.1912	2.325758	141.9314	4.190476	21	2.3	ada		ada	
				7	14.6	116	11.9	78.5	8	13.1	11.461	1.168	1.9126	5.992366	60.65042	1.6375	20	110.02	ada			

No	Nama	P/L	Usia	Onset (hari)	Leukosit	Platelet	MPV	Neutrofil	Monosit	Limfosit	Neutrofil Absolute	Monosit Absolute	Limfosit Absolute	RNL	RPL	RLM	HU	Volume Infark (cm3)	HT	HF	Merokok	Dislipidemia
111	MK	L	21	7	9.5	210	10.3	71	4.3	22.6	6.745	0.4085	2.147	3.141593	97.8109	5.255814	20	8.52	ada			ada
112	SDB	P	63	1	14	268	9.9	58.5	4.6	32.2	8.19	0.644	4.508	1.81677	59.44987	7	20	1.5	ada			ada
113	HJ.S	P	51	3	8.7	384	9.2	57	6.2	35.1	4.959	0.5394	3.0537	1.623932	125.7491	5.66129	14	2.31	ada			
114	SS	L	65	1	13.5	185	9.9	79.9	9.5	10.1	10.7865	1.2825	1.3635	7.910891	135.6802	1.063158	22	1.05	ada			
115	RA	L	70	1	8.2	226	8.9	60.1	8.8	29.5	4.9282	0.7216	2.419	2.037288	93.42704	3.352273	17	1.92	ada			
116	AA	L	64	7	4.8	263	9.1	49.4	10.8	29.9	2.3712	0.5184	1.4352	1.652174	183.2497	2.768519	17	3.2	ada			
117	IEP	L	64	20 jam	7.1	209	8.9	72.9	7.2	18.2	5.1759	0.5112	1.2922	4.005495	161.7397	2.527778	18	30.65	ada	ada		
118	H	L	64	2	13.5	187	10.4	76.1	8.4	15.1	10.2735	1.134	2.0385	5.039735	91.73412	1.797619	15	10.72			ada	
119	S	L	45	2	12.7	231	10.7	86.9	4.9	7.2	11.0363	0.6223	0.9144	12.06944	252.6247	1.469388	23	123.89	ada			
120	NS	P	63	1	9.8	293	8.6	64.1	8.3	22.5	6.2818	0.8134	2.205	2.848889	132.8798	2.710843	18	3.08	ada			ada
121	BT	L	63	7	7.6	301	8.4	54.3	10.8	25.1	4.1268	0.8208	1.9076	2.163347	157.7899	2.324074	17	1.6	ada			
122	AS	L	40	3	11.4	289	8.7	73	10.8	13.4	8.322	1.2312	1.5276	5.447761	189.1857	1.240741	20	49.84	ada	ada		
123	S	P	62	3	9.4	160	9.1	79.3	0.7	7.9	7.4542	0.0658	0.7426	10.03797	215.4592	11.28571	16	101.6	ada	ada		
124	MY	L	43	2	14.4	130	10.2	80.8	6.5	12.4	11.6352	0.936	1.7856	6.516129	72.80466	1.907692	18	119.64		ada		ada
125	S	L	41	4	6.3	227	9.1	63	10.5	24.1	3.969	0.6615	1.5183	2.614108	149.5093	2.295238	17	8.53	ada			
126	S	P	36	5	7.9	205	8.4	71.7	8.9	17.7	5.6643	0.7031	1.3983	4.050847	146.6066	1.988764	20	60.82				ada

Lampiran 3
Hasil Analisis statistik
Karakteristik Sampel Penelitian

JK	Laki-laki	n	75
		%	59.5%
	Perempuan	n	51
		%	40.5%
Kat_Usia	18-24	n	1
		%	0.8%
	25-44	n	17
		%	13.5%
	45-59	n	53
		%	42.1%
	> 60	n	55
		%	43.7%
HT	Ya	n	97
		%	77.0%
	Tidak	n	29
		%	23.0%
HF	Ya	n	19
		%	15.1%
	Tidak	n	107
		%	84.9%
Merokok	Ya	n	13
		%	10.3%
	Tidak	n	113
		%	89.7%
Dislipidemia	Ya	n	30
		%	23.8%
	Tidak	n	96
		%	76.2%
Jumlah		n	126
		%	100.0%

	Mean	SD	Median	Minimum	Maximum
Usia	56.75	10.11	57.50	21.00	70.00
Onset	2.67	2.13	2.00	1.00	7.00
Leukosit	10.67	3.89	9.80	4.30	24.80
platelet	258.44	84.44	247.50	84.00	722.00
MPV	9.61	0.90	9.40	8.00	12.40
neutrofil	69.65	12.38	70.80	41.20	93.70
monosit	7.28	2.59	7.05	0.70	13.50
limfosit	19.81	9.83	18.70	1.70	50.00
Neut_Abs	7.72	3.86	6.73	2.31	21.25
Mono_Abs	0.75	0.32	0.71	0.07	2.06
Limf_Abs	1.90	0.87	1.83	0.29	5.29
RNL	5.66	6.45	3.75	0.86	53.76
RPL	162.79	92.66	142.34	41.41	616.60
RLM	3.00	1.75	2.73	0.27	11.29
HU	19.90	3.09	20.00	14.00	32.00
Volume_Infark	53.80	97.94	3.46	0.28	534.92

Perbandingan Berdasarkan Onset (hari)

	≤ 3 hari					4-7					Nilai p
	Mean	SD	Median	Minimum	Maximum	Mean	SD	Median	Minimum	Maximum	
Usia	57.64	9.24	58.00	36.00	70.00	54.35	11.97	56.50	21.00	70.00	0.229**
Leukosit	10.57	3.52	9.80	4.30	22.00	10.94	4.80	9.60	4.80	24.80	0.783**
platelet	261.45	85.17	251.50	84.00	722.00	250.32	83.14	228.50	116.00	489.00	0.265**
MPV	9.53	0.83	9.40	8.00	12.10	9.85	1.03	9.75	8.40	12.40	0.159**
neutrofil	70.42	12.50	72.60	41.20	93.70	67.57	12.01	68.65	47.00	91.40	0.254*
monosit	6.98	2.55	7.00	0.70	13.10	8.09	2.56	7.90	4.30	13.50	0.032*
limfosit	19.70	10.19	18.65	3.20	50.00	20.09	8.91	19.15	1.70	37.50	0.844*
Neut_Abs	7.70	3.60	6.95	2.31	20.61	7.76	4.54	6.61	2.37	21.25	0.556**
Mono_Abs	0.72	0.31	0.70	0.07	1.55	0.83	0.34	0.78	0.38	2.06	0.081**
Limf_Abs	1.88	0.84	1.81	0.51	4.51	1.96	0.95	1.88	0.29	5.29	0.656*
RNL	5.61	5.22	3.87	0.86	29.28	5.82	9.07	3.41	1.34	53.76	0.442**
RPL	166.48	95.96	141.66	55.34	616.60	152.81	83.59	146.53	41.41	486.23	0.485**
RLM	3.15	1.89	2.89	0.49	11.29	2.59	1.20	2.50	0.27	5.26	0.232**
HU	19.88	3.26	20.00	14.00	32.00	19.94	2.58	20.00	16.00	26.00	0.803**
Volume_Infark	50.02	97.63	2.71	0.28	534.92	64.04	99.50	8.53	0.85	369.28	0.035**

*** Uji t Independen**
**** Uji Mann Whitney**

Hubungan RNL, RPL, RLM dan MPV dengan HU dan Volume Infark

		HU	Volume_Infark
RNL	Nilai r	0.229	0.607
	Nilai p	0.010	0.000
RPL	Nilai r	0.137	0.330
	Nilai p	0.126	0.000
RLM	Nilai r	-0.249	-0.552
	Nilai p	0.005	0.000
MPV	Nilai r	0.077	0.187
	Nilai p	0.390	0.036
* Uji Korelasi Spearman			

DAFTAR SINGKATAN

Istilah	Arti dan Penjelasan
RNL	Rasio Neutrofil Limfosit
RPL	Rasio Platelet Limfosit
RLM	Rasio Limfosit Monosit
MPV	Mean Platelet Volume
HU	Hounsfield Unit
DAMP	Damage Associated Molecular Pattern
MMP	Metalloprotease
IL	Interleukin
VCAM-1	Vascular Cell Adhesion Molecue 1
ICAM-1	Intracellular Adhesion Molecule 1
BDNF	Brain Derived Neurotrophic Factor
MCP	Monocyte Chemoattractant Protein
TNF	Tumor Necrosis Factor
ATP	Adenosine Triphosphate
CCL	C-C Motif Chemokine Ligand
CCR	C-C Motif Chemokine Receptor
CNS	Central Nervous System
G-CSF	Granulocyte Colonystimulating Factor
GM-CSF	Granulocyte–Macrophage Colony-Stimulating Factor
LFA-1	Lymphocyte Function-Associated Antigen 1
LPS	Lipopolysaccharide
MCP1P1	Monocyte Chemoattractant Protein-1 Induced Protein 1
M-CSF	Macrophage Colony-Stimulating Factor
P2X4R	Purinergic Receptor P2x4
PSGL-1	P-Selectin Glycoprotein Ligand 1
TGF-B	Transforming Growth Factor-Beta
TNF-A	(Tumor Necrosis Factor-Alpha),
VLA-4	Very Late Antigen 4
BBB	Blood Brain Barier
GP	Glikoprotein
VWF	Von Willebrand Factor
HK	High Kininogen
MAC-1	Macrophage-1
ASPECTS	Alberta Stroke Program Early Ct Score